Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$190.37 -2.0%	$178.20	$111.09 ▼ $199.99	$11.65B	0.41	494,088 shs	353,974 shs
DBV Invesco DB G10 Currency Harvest Fund	$25.41	$25.41	$24.25 ▼ $28.40	$25.41M	0.23	27,852 shs	N/A
NBY NovaBay Pharmaceuticals	$0.91 -0.4%	$0.64	$0.44 ▼ $1.25	$5.28M	0.4	1.31 million shs	759,372 shs
RTI RTI International Metals		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	-2.03%	+16.02%	+19.94%	+39.10%
DBV Invesco DB G10 Currency Harvest Fund	0.00%	0.00%	0.00%	0.00%	0.00%
NBY NovaBay Pharmaceuticals	0.00%	+47.38%	+35.35%	+59.75%	+72.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	3.4296 of 5 stars	4.5	1.0	0.0	0.0	4.1	1.7	0.6
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	0.3588 of 5 stars	1.5	0.0	0.0	0.0	0.6	0.0	1.3
RTI RTI International Metals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$243.36	27.83% Upside
DBV Invesco DB G10 Currency Harvest Fund	0.00	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-6.23% Downside
RTI RTI International Metals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RTI, ASND, DBV, and NBY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$254.00 ➝ $260.00
8/8/2025	ASND Ascendis Pharma A/S	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	ASND Ascendis Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$289.00 ➝ $295.00
8/8/2025	ASND Ascendis Pharma A/S	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$243.00 ➝ $290.00
8/8/2025	ASND Ascendis Pharma A/S	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$210.00 ➝ $230.00
8/8/2025	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$306.00 ➝ $307.00
8/8/2025	ASND Ascendis Pharma A/S	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$212.00 ➝ $220.00
8/8/2025	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $203.00
8/8/2025	ASND Ascendis Pharma A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$212.00 ➝ $254.00
7/29/2025	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$245.00 ➝ $254.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$490.75M	23.74	N/A	N/A	($1.88) per share	-101.26
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
RTI RTI International Metals	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$5.16	N/A	793.21	N/A	-54.94%	N/A	-24.31%	11/13/2025 (Estimated)
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
RTI RTI International Metals	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest RTI, ASND, DBV, and NBY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	ASND Ascendis Pharma A/S	-$1.42	-$0.93	+$0.49	-$0.93	$163.17 million	$216.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RTI RTI International Metals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.02	0.69
DBV Invesco DB G10 Currency Harvest Fund	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
RTI RTI International Metals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
DBV Invesco DB G10 Currency Harvest Fund	85.24%
NBY NovaBay Pharmaceuticals	23.25%
RTI RTI International Metals	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
DBV Invesco DB G10 Currency Harvest Fund	N/A
NBY NovaBay Pharmaceuticals	0.10%
RTI RTI International Metals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,017	61.21 million	36.73 million	Optionable
DBV Invesco DB G10 Currency Harvest Fund	80	1.00 million	N/A	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
RTI RTI International Metals	N/A	N/A	N/A	Not Optionable

RTI, ASND, DBV, and NBY Headlines

Recent News About These Companies

RTI International CEO on drastic funding cuts and his NC nonprofit’s market pivot

June 27, 2025 | msn.com

Lightstorm finishes integrating subsea cables bought from RTI

May 9, 2025 | datacenterdynamics.comD

RTI INTERNATIONAL METALS (NYSE: RTI) - Share Price and Research

May 6, 2025 | intelligentinvestor.com.auI

RTI International layoffs expected to reach at least 525 by May 1, organization says

March 27, 2025 | wral.comW

RTI International layoff expected to reach at least 525 by May 1, organization says

March 27, 2025 | msn.com

Open Source: RTI International CEO makes seven figures. Does that justify USAID cuts?

February 21, 2025 | msn.com

RTI International to temporarily lay off staff due to US foreign aid freeze

February 14, 2025 | wunc.orgW

RTI International lays off US workers, including in NC, citing Trump’s USAID cuts

February 13, 2025 | msn.com

RTI International layoffs hit NC due to US freeze on foreign aid

February 13, 2025 | wral.comW

Research Urges Tyre Particles as Unique Eco Threat

November 14, 2024 | miragenews.comM

A digital exam reels in engraved scenes of Stone Age net fishing

November 7, 2024 | sciencenews.orgS

Russia explores creation of international precious metals exchange

October 26, 2024 | msn.com

Russia in talks with BRICS over precious metals exchange

October 24, 2024 | reuters.com

RTI Joins the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA)

October 22, 2024 | markets.businessinsider.com

RTI Awarded Elite Supplier Status by Lockheed Martin's Rotary and Mission Systems (RMS) Division

October 15, 2024 | tmcnet.com

Analysts Conflicted on These Materials Names: Coeur Mining (CDE), RPM International (RPM) and Rio Tinto Limited (OtherRTNTF)

October 10, 2024 | markets.businessinsider.com

Energy transition story rekindles fund interest in metals

October 7, 2024 | reuters.com

Jai Bhim Nagar Demolition: Mumbai Police To File FIR Against BMC Officers And Policemen

October 4, 2024 | msn.com

RTI International Teams Up with USAID, UNICEF to Create a Lead-Free Future

October 4, 2024 | morningstar.comM

Mumbai: BMC Reveals Construction Of Two-Level Underground Parking Lot At Breach Candy In Response To RTI Amid Resident Concerns

October 3, 2024 | freepressjournal.inF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RTI, ASND, DBV, and NBY Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$190.37 -3.93 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$190.26 -0.12 (-0.06%)

As of 05:54 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV

$25.41 0.00 (0.00%)

As of 03/10/2023

PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.

NovaBay Pharmaceuticals NYSE:NBY

$0.91 0.00 (-0.40%)

As of 03:59 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

RTI International Metals NYSE:RTI

RTI International Metals, Inc. is a producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components for the national and international aerospace, defense, energy, medical device, and other consumer and industrial markets. The Company operates in two segments: the Titanium segment and Engineered Products and Services (EP&S) segment. The Titanium Segment melts, processes, produces, forges, stocks, distributes, finishes, cuts-to-size, and facilitates just-in-time delivery services of a complete range of titanium mill products, which are further processed by its customers for use in a variety of commercial aerospace, defense, and industrial and consumer applications. The EP&S Segment is comprised of companies with significant hard and soft-metal expertise that form, extrude, fabricate, machine, additively manufacture, micro-machine, and assemble titanium, aluminum, and other specialty metal parts and components.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time